RCMNY
RNAC icon

Rubric Capital Management (New York)’s Cartesian Therapeutics RNAC Stock Holding History

Rubric Capital Management (New York)’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-24,042
Closed -$815K – 93
2022
Q4 		$815K Hold
24,042
– – 0.04% 92
2022
Q3 		$1.18M Hold
24,042
– – 0.06% 83
2022
Q2 		$945K Buy
+24,042
New +$713K 0.05% 85

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rubric Capital Management (New York)'s RNAC Position: Q1 2023 in Review

Rubric Capital Management (New York) sold out of Cartesian Therapeutics (RNAC) in Q1 2023, closing a stake of 24,042 shares — an estimated $815K sold.

Rubric Capital Management (New York) first reported a position in RNAC in Q2 2022 and held it in 3 quarters. The position peaked at $1.18M in Q3 2022. 93 funds tracked by Wall St. Rank hold RNAC as of Q1 2023.

  • Rubric Capital Management (New York) reported no remaining Cartesian Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 24,042 Cartesian Therapeutics shares in Q1 2023, an estimated $815K.
  • Rubric Capital Management (New York) first reported a position in Cartesian Therapeutics in Q2 2022 and held it in 3 quarters.
  • Rubric Capital Management (New York)'s Cartesian Therapeutics position peaked at $1.18M in Q3 2022.
  • 93 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2023, filed 12 May 2023.